AUTO-1-NG

N/A

Report date: 2024/03/26 16:19:58

Base Information

Drug NameAUTO-1-NG
Drug Alias NameCD19/22 CAR T-cells therapy(University College London)CD19/22 CAR Redirected T-cells therapy(University College London)AUTO-1-NGAUTO1/22
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD22 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAutolus Therapeutics PlcUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesAutolus Therapeutics PlcUniversity College LondonBiontech Se
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A